According to a July 19 Frontera Therapeutics press release provided to Becker’s, Frontera Therapeutics specializes in creating gene therapy candidates for various diseases. In addition to the fundraising announcement, Frontera Therapeutics confirmed that the FDA accepted the company’s application to begin human clinical trials for their gene therapy drug designed to treat rare genetic retinal disease.
The financing will create new manufacturing capabilities and investment in clinical development.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
